Daily Market Reports | 10:34 AM
An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities.
In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Australian Broker Call *Extra* Edition, featuring additional sources of research and insights on ASX-listed stocks, also enlarging the number of stocks that make up the FNArena universe.
One key difference is the *Extra* Edition will not be updated daily, but merely "regularly" depending on availability of suitable quality content. As such, the *Extra* Edition tries to build a bridge between daily updates via the Australian Broker Call Report and ad hoc news stories, that are not always timely for investors hungry for the next information update.
Investors using the *Extra* Edition as a source of input for their own share market research should thus take into account that information after publication may not be up to date, or yet awaiting another update by FNArena's team of journalists.
Similar to The Australian Broker Call Report, this *Extra* Edition includes concise but limited reviews of research recently published by Stockbrokers and other experts, which should be considered as information concerning likely market behaviour rather than advice on the securities mentioned. Do not act on the contents of this Report without first reading the important information included at the end of this Report.
The Australian Broker Call *Extra* Edition is a summary that has been prepared independently of the sources identified. Readers will check the full text of the recommendations and consult a Licenced Advisor before making any investment decision.
The copyright of this Report is owned by the publisher. Readers will not copy, forward or disseminate this Report to any other person. For more vital information about the sources included, see the bottom of this Report.
COMPANIES DISCUSSED IN THIS ISSUE
Click on a symbol for fast access.
The number next to the symbol represents the number of brokers covering it for this report -(if more than 1)
ABB ACE CSL D2O ELD EMR GMG IPD MM8 NWH PNR RMD SOM SRG
ACE ACUSENSUS LIMITED
Transportation & Logistics - Overnight Price: $1.76
Canaccord Genuity rates ((ACE)) as Buy (1) -
Canaccord Genuity notes Acusensus has announced its largest US contract with a five-year US$23m program for automated workzone speed enforcement in Connecticut.
Post a long tender process, the company succeeded in beating the incumbent operator Verra Mobility, who operated the initial pilot program.
The analyst believes the contract reinforces Acusensus' technology in the US market and sees further opportunities in other states where new legislation is now in place, including Kentucky, Michigan, and Vermont.
Target price is lifted higher to $2 from $1.65 and Buy rating remains unchanged. The analyst also lifts its revenue forecasts by 3% for FY27 and 7% for both FY27 and FY28.
This report was published on October 7, 2025.
Target price is $2.00 Current Price is $1.76 Difference: $0.24
If ACE meets the Canaccord Genuity target it will return approximately 14% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 1.40 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 125.71.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of minus 0.10 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 1760.00.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
CSL CSL LIMITED
Pharmaceuticals & Biotech/Lifesciences - Overnight Price: $216.45
Jarden rates ((CSL)) as Overweight (2) -
CSL reported the loss of a large NHS Ig contract, offset by a tender victory in Australia for Ig supply worth $1.1bn.
Jarden expects the pricing for this contract extension will be better than the original contract pricing negotiated pre-covid in 2020, and the volume may offer gross margin upside to Behring.
The biotech has also won a tender with the National Blood Authority to supply $73.6m of Idelvion over three years from July 2025.
Jarden highlights none of the tender wins are included in current forecasts, with the contract extension only at the end of September, but views there to be upside potential for management's FY26 net profit after tax guidance in constant currency terms.
Target rises to $304.17 from $298.13. Overweight rating retained.
This report was published on October 13, 2025.
Target price is $304.17 Current Price is $216.45 Difference: $87.72
If CSL meets the Jarden target it will return approximately 41% (excluding dividends, fees and charges).
Current consensus price target is $275.39, suggesting upside of 27.2%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 366.31 cents and EPS of 846.79 cents.
At the last closing share price the estimated dividend yield is 1.69%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 25.56.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 1114.6, implying annual growth of N/A.
Current consensus DPS estimate is 504.6, implying a prospective dividend yield of 2.3%.
Current consensus EPS estimate suggests the PER is 19.4.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 508.48 cents and EPS of 1130.66 cents.
At the last closing share price the estimated dividend yield is 2.35%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 19.14.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 1255.0, implying annual growth of 12.6%.
Current consensus DPS estimate is 554.4, implying a prospective dividend yield of 2.6%.
Current consensus EPS estimate suggests the PER is 17.2.
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
D2O DUXTON WATER LIMITED
Agriculture - Overnight Price: $1.53
Petra Capital rates ((D2O)) as Buy (1) -
Petra Capital scans across the latest winter rain updates, noting the winter period has failed to refill dam levels ahead of the season drawdown.
The robust snow season will provide some offset in terms of melt, but above-average rainfall is now required to lift dam levels, and the BOM has recently forecast a weak La Niña in spring.
Duxton Water continues to be well positioned to reap the benefits of ongoing dry conditions. The analyst proposes the company’s earnings and cash flow should benefit as Australia moves away from a period dominated by La Niñas.
Buy rating retained with a $2.08 target price.
This report was published on October 13, 2025.
Target price is $2.08 Current Price is $1.53 Difference: $0.55
If D2O meets the Petra Capital target it will return approximately 36% (excluding dividends, fees and charges).
The company's fiscal year ends in December.
Forecast for FY25:
Petra Capital forecasts a full year FY25 dividend of 7.40 cents and EPS of 18.40 cents.
At the last closing share price the estimated dividend yield is 4.84%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 8.32.
Forecast for FY26:
Petra Capital forecasts a full year FY26 dividend of 7.70 cents and EPS of 10.00 cents.
At the last closing share price the estimated dividend yield is 5.03%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 15.30.
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
The full story is for FNArena subscribers only. To read the full story plus enjoy a free two-week trial to our service SIGN UP HERE
If you already had your free trial, why not join as a paying subscriber? CLICK HERE